Clinical Trial Update: NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating NIAGEN (nicotinamide riboside) for persistent chemotherapy-induced peripheral neuropathy. The study is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• Niagen®+ (nicotinamide riboside)

Snippet

Sponsor: Donna Hammond, PhD | Conditions: Chemotherapy-induced Peripheral Neuropathy | Phase 2 | Status: ACTIVE_NOT_RECRUITING